BIM-23190, a somatostatin analog, a selective SSTR2 and SSTR5 agonist, exhibits K i values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly.

BIM-23190 tends to mildly stimulate PRL secretion[1].

BIM-23190 (50 μg/mouse, twice a day) exhibits significant anti-tumor (C6 glioma) activity[2]. Animal Model: Male athymic nude (nu/nu) mice, 5-6 wk old (C6 glioma)[2]. Dosage: 50 μg/mouse Administration: Injected twice a day for 19 days. Result: Significantly reduced the tumor growth rate.

182153-96-4

C57H79N13O12S2

1202.46

BIM-23190

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years